Nitazoxanide in the Treatment of COVID-19: A paradigm for Antiviral Drugs Targeting Host-Infected Cells
Christian Brechot, Jean-Francois Rossignol
doi:10.18103/mra.v
Despite significant breakthroughs in the discovery of direct-acting antivirals for several viruses, there is a need for improvement. Thus, drugs able to target host-infected cells may prove valuable in enhancing the efficacy of antivirals and avoiding resistance due to viral genetic changes. In this context, we summarize in this review the current knowledge on nitazoxanide's potential for treating COVID-19. Our review highlights nitazoxanide's very specific mode of action, targeting cellular energy through inhibiting mitochondrial oxidative phosphorylation (OXPHOS) and stimulating the innate immune response. Thus, nitazoxanide lowers the cellular ATP content and this leads to impaired viral replication and assembly. However, since nitazoxanide only yields a mild OXPHOS inhibition, this does not affect cell viability. Preclinical results and some clinical studies have suggested that nitazoxanide might be helpful for treating COVID-19. Indeed, some clinical studies have shown a decrease in severe COVID19 evolution as well as in viral multiplication; yet the results are still debated. Overall, the available information suggests the potential of nitazoxanide in association with direct-acting antivirals. In fact, this may hold true for other viruses than SARS-CoV-2 in the future. The impact of nitazoxanide on COVID-19 should be viewed as a paradigm for antiviral drugs targeting host-infected cells, and nitazoxanide should be part of the therapeutic tools for future emerging virus-related pandemics. Nitazoxanide in the Treatment of COVID-19
References
Abuelazm, Ghanem, Awad, Abdelmoez Farahat, Labieb et al., The Effect of Nitazoxanide on the Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled, Trials Clinical Drug Investigation,
doi:10.1007/s40261-022-01213-yBlum, Cimerman, Hunter, Nitazoxanide superiority to placebo to treat Nitazoxanide in the Treatment of COVID-19 moderate COVID-19 -A Pilot prove of concept randomized double-blind clinical trial, EClinicalMedicine,
doi:10.1016/j.eclinm.2021.100981Escalera, Gonzalez-Reiche, Aslam, SARS-CoV-2 variants of concern have acquired mutations associated with an increased spike cleavage, bioRxiv,
doi:10.1101/2021.08.05.455290Haffizulla, Hartman, Hoppers, Effect of nitazoxanide in adults and adolescents with acute uncomplicated influenza: a double-blind, randomised, placebocontrolled, phase 2b/3 trial, Lancet Infect Dis,
doi:10.1016/S1473-3099(14)70717-0Jasenosky, Cadena, Mire, The FDA-Approved Oral Drug Nitazoxanide Amplifies Host Antiviral Responses and Inhibits Ebola Virus, iScience,
doi:10.1016/j.isci.2019.07.003Keusch, Amuasi, Anderson, Pandemic origins and a One Health approach to preparedness and prevention: Solutions based on SARS-CoV-2 and other RNA viruses, Proc Natl Acad Sci U S A,
doi:10.1073/pnas.2202871119Leventhal, Clancy, Erasmus, Feldmann, Hawman, An Intramuscular DNA Vaccine for SARS-CoV-2 Decreases Viral Lung Load but Not Lung Pathology in Syrian Hamsters, Microorganisms,
doi:10.3390/microorganisms9051040Lopez, Calderon, Avila, Evolution of COVID-19 Pregnancies Treated with Nitazoxanide in a Third-Level Hospital, Cureus,
doi:10.7759/cureus.15002Martins-Filho, Do Nascimento-Junior, Barreto-Alves, Fakhouri, Ferreira, Efficacy and safety of nitazoxanide in treating SARS-CoV-2 infection: a systematic review and meta-analysis of blinded, placebo-controlled, randomized clinical trials, Eur J Clin Pharmacol,
doi:10.1007/s00228-022-03380-5Miorin, Mire, Ranjbar, The oral drug nitazoxanide restricts SARS-CoV-2 infection and attenuates disease pathogenesis in Syrian hamsters, bioRxiv,
doi:10.1101/2022.02.08.479634Piacentini, Riccio, Santopolo, The FDA-approved drug nitazoxanide is a potent inhibitor of human seasonal coronaviruses acting at postentry level: effect on the viral spike glycoprotein, bioRxiv,
doi:10.1101/2022.07.13.499346Pouysségur, Marchiq, Parks, Durivault, Ždralević et al., Warburg effect' controls tumor growth, bacterial, viral infections and immunity -Genetic deconstruction and therapeutic perspectives, Semin Cancer Biol,
doi:10.1016/j.semcancer.2022.07.004Ranjbar, Haridas, Nambu, Cytoplasmic RNA Sensor Pathways and Nitazoxanide Broadly Inhibit Intracellular Mycobacterium tuberculosis Growth, iScience,
doi:10.1016/j.isci.2019.11.001Riccio, Santopolo, Rossi, Piacentini, Rossignol et al., Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by nitazoxanide: an effect independent of spike variants emergence, Cell Mol Life Sci,
doi:10.1007/s00018-022-04246-wRocco, Silva, Cruz, Early use of nitazoxanide in mild COVID-19 disease: randomised, placebo-controlled trial, Eur Respir J,
doi:10.1183/13993003.03725-2020Rocco, Silva, Cruz, Nitazoxanide in Patients Hospitalized With COVID-19: A Multicentre, Randomized, Double-Blind, Placebo-Controlled Trial, Front Med,
doi:10.3389/fmed.2022.844728Rossignol, Bardin, Fulgencio, Mogelnicki, Brechot, A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19, EClinicalMedicine,
doi:10.1016/j.eclinm.2022.101310Rossignol, Cavier, Synthesis and antiparasitic activity of 2-benzamido nitrothiazoles
Rossignol, Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus, J Infect Public Health,
doi:10.1016/j.jiph.2016.04.001Senkowski, Zhang, Olofsson, Three-Dimensional Cell Culture-Based Screening Identifies the Anthelmintic Drug Nitazoxanide as a Candidate for Treatment of Colorectal Cancer, Mol Cancer Ther,
doi:10.1158/1535-7163Silva, Espejo, Pereyra, Efficacy of Nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebocontrolled, single-blinded, parallel group, pilot study, medRxiv,
doi:10.1101/2021.03.03.21252509Stockis, Deroubaix, Lins, Jeanbaptiste, Calderon et al., Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers, Int J Clin Pharmacol Ther
Tan, Hu, Luquette, Systematic identification of synergistic drug pairs targeting HIV, Nat Biotechnol,
doi:10.1038/nbt.2391Trabattoni, Gnudi, Ibba, Thiazolides Elicit Anti-Viral Innate Immunity and Reduce HIV Replication, Sci Rep,
doi:10.1038/srep27148Wang, Cao, Zhang, Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro, Cell Res. Mar,
doi:10.1038/s41422-020-0282-0
